Expanding on previously reported results in the overall population, new prespecified subgroup analyses showed greater Week 24 combined fistula remission with TREMFYA versus placebo among: 1 Perianal ...
Remission and Endoscopic Response with RINVOQ for Advanced and Difficult-to-Treat Crohn's Disease ...
ABBV's Skyrizi and Rinvoq are expected to drive Q3 growth, offset Humira's ongoing decline and face rising competition in the ...
The data include new Phase 3 AFFIRM findings for SKYRIZI (risankizumab-rzaa) in advanced therapy-naïve Crohn's disease (CD) patients, as well as open-label extension analyses demonstrating long-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results